Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Consensus Recommendation of “Buy” from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have covered the stock in the last year is $37.17.

Several brokerages recently issued reports on KNSA. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares of the company’s stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 93,766 shares of company stock worth $2,011,735. 54.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Quarry LP acquired a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth about $50,000. Lazard Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $61,000. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $158,000. Bellevue Group AG acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth approximately $160,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after purchasing an additional 4,575 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $20.36 on Monday. The business’s 50-day simple moving average is $21.00 and its two-hundred day simple moving average is $21.84. The company has a market cap of $1.48 billion, a PE ratio of -145.42 and a beta of 0.31. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same quarter last year, the company posted $0.35 EPS. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% compared to the same quarter last year. As a group, analysts predict that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.